Cargando…
Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis
Background: Immune checkpoint inhibitors targeting the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway are a paradigm-shifting cancer therapy. Programmed cell death ligand 2 (PD-L2) is another ligand of PD-1, but its prognostic significance in solid cancer patients afte...
Autores principales: | Yang, Huayu, Zhou, Xiaoxiang, Sun, Lejia, Mao, Yilei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413700/ https://www.ncbi.nlm.nih.gov/pubmed/30891423 http://dx.doi.org/10.3389/fonc.2019.00047 |
Ejemplares similares
-
The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis
por: Xu, Gang, et al.
Publicado: (2019) -
The Impacts of Systemic Immune-Inflammation Index on Clinical Outcomes in Gallbladder Carcinoma
por: Sun, Lejia, et al.
Publicado: (2020) -
Patient-derived organoids: a promising model for personalized cancer treatment
por: Yang, Huayu, et al.
Publicado: (2018) -
Galectin-9 Expression Predicts Favorable Clinical Outcome in Solid Tumors: A Systematic Review and Meta-Analysis
por: Zhou, Xiaoxiang, et al.
Publicado: (2018) -
The Association Between the Incidence Risk of Peripheral Neuropathy and PD-1/PD-L1 Inhibitors in the Treatment for Solid Tumor Patients: A Systematic Review and Meta-Analysis
por: Si, Zhihua, et al.
Publicado: (2019)